$14.50 -0.91 (-5.91%)
2/10/2012 4:00 PM

InterMune, Inc. (NASDAQ:ITMN)

CAPS Rating: 2 out of 5

The Company is a biotech company focused on developing and commercializing innovative therapies in pulmonology and hepatology.

Featured Broker Partners


Advertisement